AstraZeneca plc (AZN) Given Consensus Rating of “Hold” by Brokerages

Share on StockTwits

AstraZeneca plc (LON:AZN) has received a consensus recommendation of “Hold” from the twenty-two brokerages that are covering the firm, Marketbeat reports. Three investment analysts have rated the stock with a sell rating, six have issued a hold rating and thirteen have issued a buy rating on the company. The average 1-year price objective among brokerages that have covered the stock in the last year is GBX 6,336.82 ($82.80).

A number of brokerages have recently weighed in on AZN. Liberum Capital restated a “hold” rating on shares of AstraZeneca in a research note on Friday, March 29th. Jefferies Financial Group reiterated a “hold” rating on shares of AstraZeneca in a research note on Thursday, March 14th. Goldman Sachs Group reiterated a “sell” rating on shares of AstraZeneca in a research note on Monday, March 18th. Barclays reiterated an “overweight” rating on shares of AstraZeneca in a research note on Monday, March 11th. Finally, Deutsche Bank reiterated a “buy” rating and set a GBX 6,900 ($90.16) target price on shares of AstraZeneca in a research note on Tuesday, February 26th.

Shares of AstraZeneca stock traded down GBX 30 ($0.39) on Friday, reaching GBX 5,988 ($78.24). The stock had a trading volume of 2,827,378 shares, compared to its average volume of 2,310,000. The company has a current ratio of 0.96, a quick ratio of 0.71 and a debt-to-equity ratio of 136.31. AstraZeneca has a fifty-two week low of GBX 4,874.50 ($63.69) and a fifty-two week high of GBX 6,540 ($85.46). The stock has a market capitalization of $78.55 billion and a price-to-earnings ratio of 35.22.

The business also recently announced a dividend, which was paid on Wednesday, March 27th. Investors of record on Thursday, February 28th were paid a dividend of GBX 146.80 ($1.92) per share. This is a boost from AstraZeneca’s previous dividend of $68.40. This represents a yield of 2.57%. The ex-dividend date of this dividend was Thursday, February 28th. AstraZeneca’s dividend payout ratio is presently 1.26%.

AstraZeneca Company Profile

AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.

Further Reading: Outstanding Shares, Buying and Selling Stocks

Analyst Recommendations for AstraZeneca (LON:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Monolithic Power Systems  Lowered to “Hold” at BidaskClub
Monolithic Power Systems Lowered to “Hold” at BidaskClub
NPER  Achieves Market Capitalization of $200,708.00
NPER Achieves Market Capitalization of $200,708.00
Bausch Health Companies  Downgraded to “Sell” at ValuEngine
Bausch Health Companies Downgraded to “Sell” at ValuEngine
Innophos  Cut to “Sell” at BidaskClub
Innophos Cut to “Sell” at BidaskClub
Bed Bath & Beyond  Lowered to Sell at BidaskClub
Bed Bath & Beyond Lowered to Sell at BidaskClub
Mindexcoin  Market Capitalization Hits $1.06 Million
Mindexcoin Market Capitalization Hits $1.06 Million


© 2006-2019 Ticker Report